BRIDGEWATER, N.J., March 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that Paul Chew, M.D., has been appointed to Chief Science Officer/Chief Medical Officer, U.S., effective April 1. He was previously President, R&D, sanofi-aventis, U.S.
As the company's Chief Science Officer and Chief Medical Officer, Paul Chew will establish a unified medical voice for sanofi-aventis U.S. among internal and external stakeholders. He will be responsible for overseeing U.S. Medical Affairs in addition to his continued oversight of the U.S. R&D organization in coordination with the Group in Paris. Further, Paul Chew will be charged with representing accurate and timely clinical and safety information to health authorities, payers, patients and physicians that will foster safe and appropriate use of our products.
Paul Chew's primary reporting will be to Greg Irace, President and Chief Executive Officer, sanofi-aventis U.S., in addition to Marc Cluzel, Group Senior Vice President of R&D and Jean-Pierre Lehner, Group Chief Medical Officer.
"Paul brings deep, scientific expertise and proven leadership to both the R&D and Medical functions in the U.S. - a critical area in which the science and the business of our industry intersect," said Greg Irace. "In this new role, Paul will be in a position to bring greater scientific and product insights to our organization, greater clarity and dialogue with members of the healthcare system and, ultimately, greater value to patients in the form of improved health outcomes."
The new role of Chief Science Officer/Chief Medical Officer is part of the company's overall organizational drive to ensure all components of the U.S. affiliate work in a coordinated manner to achieve harmonized processes, cost-effectiveness and best practice sharing in the design, conduct and monitoring of clinical studies.
Copyright©2009 PR Newswire.
All rights reserved